Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook Bone Biologics (NASDAQ: BBLG) summarized 2025 operational, scientific, and corporate milestones and provided a 2026 outlook. Key 2025 achievements include extending validated shelf life of its rhNELL-1 protein to 24 months, completing a registered public offering raising $5.0 million in Q2 2025, filing a U.S. patent application for its rhNELL-1 bone regeneration technology, and regaining Nasdaq minimum bid price compliance in June 2025. For 2026 the company plans to advance its NB1 clinical program with expected completion of patient enrollment in its first-in-human trial, continue manufacturing and regulatory readiness efforts, pursue additional patent protection, and maintain capital discipline.

#BBLG #BBLGW Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

www.stocktitan.net/news/BBLG/bone-biologics...

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets,

#BBLG #BBLGW Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

www.stocktitan.net/news/BBLG/bone-biologics...

$5M Funding Secured: Bone Biologics Advances Revolutionary Spine Fusion Treatment with Extended Shelf Life Biotech firm advances NB1 spine fusion treatment trial in Australia, achieves 18-month shelf life, raises $5M. Cash runway extended to Q2 2026. Trial enrollment completion expected by year-end.

#BBLG #BBLGW Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

www.stocktitan.net/news/BBLG/bone-biologics...

Bone Biologics Announces Pricing of $5.0 Million Public Offering Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, has announced the pricing of a $5.0 million public offering. The offering consists of 1,250,000 shares of common stock (or equivalents) at $4.00 per share, along with Series D and Series E warrants.The offering includes Series D warrants with a 5-year term and Series E short-term warrants with an 18-month term, both with an exercise price of $4.00 per share. If fully exercised, the warrants could provide additional gross proceeds of $10.0 million. The company plans to use the proceeds for clinical trials, patent portfolio maintenance, and working capital.

#BBLG #BBLGW Bone Biologics Announces Pricing of $5.0 Million Public Offering

www.stocktitan.net/news/BBLG/bone-biologics...

Game-Changing Bone Regeneration Patent: Bone Biologics Advances New Spine Fusion Treatment Bone Biologics files USPTO patent for NELL-1 protein technology, advancing spine fusion treatment innovation. See how this breakthrough could transform orthopedic care.

#BBLG #BBLGW Bone Biologics Files Patent Application for Bone Regeneration Technology

www.stocktitan.net/news/BBLG/bone-biologics...

Bone Biologics Finalizes 1-for-6 Reverse Split: Key Details for Nasdaq Biotech Investors Stockholder-approved 1:6 reverse split takes effect June 10. New CUSIP, adjusted warrants, no fractional shares. Get complete implementation details.

#BBLG #BBLGW Bone Biologics Announces 1-for-6 Reverse Stock Split

www.stocktitan.net/news/BBLG/bone-biologics...

BREAKING NEWS: ( NASDAQ: #BBLGW ) Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

#StockMarket #News